MDXG Q1 2023 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+21.7% YoY

Gross Profit

$59M82.7% margin

Operating Income

-$340,000-0.5% margin

Net Income

-$5M-7.0% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

-3.6%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$168M

Total Liabilities

$94M

Stockholders' Equity

$75M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$59M	+21.7%
Gross Profit	$59M	$49M	+21.0%
Operating Income	-$340,000	-$9M	+96.3%
Net Income	-$5M	-$10M	+52.5%

Revenue Segments

Advanced Wound Care

$71M50%

Advanced Wound Care, Tissue And Other

$66M46%

Advanced Wound Care, Umbilical Cord-Derived

$5M4%

Section 351

$466,0000%